Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors-Reference-Cited by-同舟云学术

Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors

Published:2023-12-18 Issue: Volume: Page:
ISSN:1590-1874
Container-title:Neurological Sciences
language:en
Short-container-title:Neurol Sci

Author:

Fionda Laura^ORCID,Rossini Elena,Lauletta Antonio,Leonardi Luca,Tufano Laura,Costanzo Rocco,Marchetti Paolo,Salvetti Marco,Garibaldi Matteo,Morino Stefania,Antonini Giovanni

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Neurology (clinical),Dermatology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10072-023-07190-0.pdf

Reference10 articles.

1. Kraehenbuehl L, Weng CH, Eghbali S, Wolchok JD, Merghoub T (2022) Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat Rev Clin Oncol 19(1):37–50

2. Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K et al (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89(11):1127–1134

3. Kao JC, Brickshawana A, Liewluck T (2018) Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors. Curr Neurol Neurosci Rep 18(10):63

4. Marini A, Bernardini A, Gigli GL, Valente M, Muñiz-Castrillo S, Honnorat J et al (2021) Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology 96(16):754–766

5. Majem M, García-Martínez E, Martinez M, Muñoz-Couselo E, Rodriguez-Abreu D, Alvarez R, Arance A et al (2020) SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019). Clin Transl Oncol 22(2):213–222

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thymus Surgery Prospectives and Perspectives in Myasthenia Gravis;Journal of Personalized Medicine;2024-02-23